Alternatives to BC Platforms

Unlike most data management systems, PHEMI Health DataLab is built with Privacy-by-Design principles, not as an add-on. This means privacy and data governance are built-in from the ground up, providing you with distinct advantages: Lets analysts work with data without breaching privacy guidelines Includes a comprehensive, extensible library of de-identification algorithms to hide, mask, truncate, group, and anonymize data. Creates dataset-specific or system-wide pseudonyms enabling linking and sharing of data without risking data leakage. Collects audit logs concerning not only what changes were made to the PHEMI system, but also data access patterns. Automatically generates human and machine-readable de- identification reports to meet your enterprise governance risk and compliance guidelines. Rather than a policy per data access point, PHEMI gives you the advantage of one central policy for all access patterns, whether Spark, ODBC, REST, export, and more

SYNTHIA™ Retrosynthesis software, developed by computer scientists and coded by chemists, allows scientists to quickly and easily navigate novel and innovative pathways for novel and previously published target molecules. You can quickly and efficiently scan hundreds pathways to identify the best options for your needs. Discover the most cost-effective route to your target molecule with the latest visualization and filtering features. You can easily customize the search parameters to eliminate or highlight reactions, reagents, or classes of molecules. Explore innovative and unique syntheses to build your desired molecule. Easy to generate a list for starting materials that are commercially available for your synthesis. ISO/IEC 27001 Information Security Certification will guarantee the confidentiality, integrity and protection of your data.

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. More than 2 million scientists and 10,000 customers trust Dotmatics to accelerate research and help make the world a healthier, cleaner, and safer place to live.

Scitara DLX™ provides a swift connectivity framework suitable for any instrument found within life science laboratories, all while operating on a cloud-based platform that is both compliant and auditable. As a versatile digital data infrastructure, Scitara DLX™ facilitates connections between various instruments, resources, applications, and software utilized in the lab. The comprehensive cloud system ensures that all data sources are interconnected, promoting seamless data movement across numerous endpoints. Consequently, researchers can concentrate on their scientific endeavors instead of being bogged down by data-related challenges. Moreover, DLX intelligently curates and corrects data as it is processed, fostering the creation of accurate and well-organized data models that are essential for enhancing AI and ML systems. This robust approach plays a vital role in advancing digital transformation strategies within the pharmaceutical and biopharmaceutical sectors. By unlocking valuable insights from scientific data, the platform accelerates decision-making processes in drug discovery and development, ultimately aiding in the expedited launch of new medications into the market. Additionally, the integration of such a sophisticated infrastructure not only streamlines workflows but also enhances collaboration among researchers, paving the way for innovative solutions in the life sciences field.

At Metabolon, we proudly provide the most extensive Level 1 library in the metabolomics field. Our unique library has been meticulously developed and refined over two decades, boasting more than 5,400 entries. The majority of these entries are classified as Level 1, comprising roughly 85% (around 4,600 entries); however, about 15% of the library consists of Level 2 entries (approximately 800 entries), which are categorized as such due to the unavailability of commercial standards necessary for Level 1 classification. Thanks to our unparalleled library size and exceptional annotation confidence, Metabolon offers precise and highly actionable insights tailored to our clients’ scientific or clinical needs. The applications of metabolomics span a broad spectrum of research areas, including soil health, nutritional studies, preclinical investigations, and clinical trials. Whether you're identifying trends within a population or fine-tuning an individual's treatment plan, metabolomics serves as a powerful tool to uncover crucial answers to pressing questions in various fields. With such extensive resources at your disposal, the potential for discovery is truly limitless.

BenevolentAI is a pioneering platform that leverages artificial intelligence and scientific technology to enhance drug discovery processes, specifically targeting complex diseases by efficiently processing and interpreting extensive biomedical data to yield actionable insights more swiftly than conventional approaches. By utilizing its unique Benevolent Platform, the company seamlessly integrates both structured and unstructured biomedical information—spanning literature, genomics, clinical data, and multi-omics—into a detailed knowledge graph. This robust framework empowers researchers to analyze biological systems, formulate testable hypotheses, identify new drug targets, and create potential drug candidates with increased confidence and reduced failure rates, ultimately transforming the landscape of medicine development. With its innovative approach, BenevolentAI stands at the forefront of a new era in the pharmaceutical industry.

Revolutionize the fields of drug discovery and materials research through cutting-edge molecular modeling techniques. Our computational platform, grounded in physics, combines unique solutions for predictive modeling, data analysis, and collaboration, facilitating swift navigation of chemical space. This innovative platform is employed by leading industries globally, serving both drug discovery initiatives and materials science applications across various sectors including aerospace, energy, semiconductors, and electronic displays. It drives our internal drug discovery projects, overseeing processes from target identification through hit discovery and lead optimization. Additionally, it enhances our collaborative research efforts aimed at creating groundbreaking medicines to address significant public health challenges. With a dedicated team of over 150 Ph.D. scientists, we commit substantial resources to research and development. Our contributions to the scientific community include more than 400 peer-reviewed publications that validate the efficacy of our physics-based methodologies, and we remain at the forefront of advancing computational modeling techniques. We are steadfast in our mission to innovate and expand the possibilities within our field.

Scispot delivers a powerful lab informatics platform that transforms how life science labs operate. Through its configurable LabOS™ ecosystem, teams can select from a unified suite of tools covering ELN, LIMS, SDMS, QMS, and AI capabilities—all accessible through an intuitive no-code interface. Purpose-built for CROs, Diagnostic Labs, and Biotech R&D teams, Scispot addresses critical challenges in Sample Management, Freezer Management, and GxP Compliance. The platform seamlessly connects with 200+ lab instruments and 7,000+ applications, eliminating manual data entry while ensuring regulatory adherence. Scispot's AI-powered analytics convert experimental data into actionable insights, accelerating discovery timelines. With rapid implementation and a focus on user experience, Scispot enables 1000+ lab scientists and operators to standardize processes, maintain compliance, and focus resources on innovation rather than administrative overhead.

Eidogen-Sertanty's Target Informatics Platform (TIP) stands out as the pioneering structural informatics system and knowledgebase that empowers researchers to explore the druggable genome through a structural lens. By harnessing the burgeoning wealth of experimental protein structure data, TIP revolutionizes structure-based drug discovery, shifting it from a limited, low-throughput field to a dynamic and data-rich scientific discipline. It is specifically designed to connect the realms of bioinformatics and cheminformatics, providing drug discovery scientists with a repository of insights that are not only unique but also highly synergistic with the information available from traditional bio- and cheminformatics tools. The platform's innovative combination of structural data management with advanced target-to-lead calculation and analytical capabilities significantly enhances every phase of the drug discovery process. With TIP, researchers are better equipped to navigate the complexities of drug development and make informed decisions.

Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.

DNAnexus Apollo™ enhances the efficiency of precision drug discovery by fostering collaboration that extracts valuable insights from omics data. The process of precision drug discovery involves the aggregation and examination of vast amounts of omics and clinical information. These extensive datasets serve as valuable assets; however, many traditional and custom-built informatics tools struggle to manage their intricacies and scale. Additionally, the effectiveness of precision medicine initiatives can be hindered by fragmented data sources, inadequate collaboration tools, and the challenges posed by complex, evolving regulatory and security demands. By enabling scientists and clinicians to jointly investigate and interpret omics and clinical data within a unified framework, DNAnexus Apollo™ bolsters precision drug discovery efforts. This platform, which is powered by a resilient and scalable cloud infrastructure, facilitates the seamless and secure sharing of data, tools, and analyses among peers and collaborators, regardless of whether they are nearby or across the globe. Ultimately, Apollo not only streamlines the data-sharing process but also enhances the overall collaborative experience in the pursuit of innovative drug discoveries.

Recursion is a leading TechBio innovator using artificial intelligence to radically improve how new medicines are discovered and developed. The company was founded on the idea that images of cells could be used to train AI systems to understand disease biology at scale. By combining data, machine learning models, and powerful computing, Recursion works to overcome the inefficiencies of traditional drug discovery. Its Recursion OS platform connects massive proprietary biological datasets with automated experimentation and AI-driven insights. This approach has produced a growing pipeline of potential therapies for oncology and rare diseases with high unmet medical needs. Recursion has demonstrated significant gains in speed, efficiency, and cost reduction compared to conventional pharmaceutical methods. Strategic partnerships with pharmaceutical companies and technology leaders expand the reach of its platform. The company also collaborates with NVIDIA to power its discovery efforts using BioHive-2, one of the most advanced supercomputers in biopharma. Together, these capabilities position Recursion as a leader in AI-driven drug discovery. Its ultimate goal is to deliver better medicines to patients through precision design and data-driven science.

GPT-Rosalind is an advanced reasoning model created by OpenAI, aimed at enhancing scientific exploration in fields like biology, drug development, and translational medicine. Tailored for workflows in life sciences, it assists researchers in managing extensive literature, experimental findings, and specialized databases to formulate and test innovative concepts. By integrating a profound understanding of disciplines such as chemistry, genomics, protein engineering, and disease biology with sophisticated tool-usage capabilities, it effectively interacts with scientific databases, examines experimental results, and facilitates intricate, multi-stage reasoning tasks. Its functionalities span evidence synthesis, hypothesis formulation, literature assessment, sequence analysis, and experimental design, empowering scientists to transition more swiftly from raw data to meaningful insights. Furthermore, GPT-Rosalind revolutionizes cumbersome, time-consuming research methodologies into streamlined, AI-enhanced workflows, ultimately fostering a more productive scientific environment. This model exemplifies the fusion of artificial intelligence with scientific inquiry, paving the way for groundbreaking discoveries.

AIDDISON™ is an innovative drug discovery software that harnesses the capabilities of artificial intelligence (AI), machine learning (ML), and advanced 3D computer-aided drug design (CADD) techniques, serving as an essential resource for medicinal chemistry applications. This comprehensive platform streamlines both ligand-based and structure-based drug design, effectively merging all components necessary for virtual screening while also facilitating in-silico lead discovery and optimization processes. By leveraging these cutting-edge technologies, AIDDISON™ significantly enhances the efficiency and effectiveness of the drug development pipeline.

Introducing IDBS Polar, the pioneering BioPharma Lifecycle Management (BPLM) platform that streamlines tedious manual operations, empowering you to carry out processes more effectively while gathering the essential data needed to speed up market entry by addressing significant hurdles in process design, optimization, scale-up, and technology transfer. This innovative platform features interactive data analytics tools, including a bioreactor comparison tool tailored for biopharma development scientists. IDBS Polar excels at securely overseeing drug progression through comprehensive workflows, seamless integration, and insightful data analysis. Its structured workflows are crafted to ease the complexities of the BioPharma Lifecycle, ensuring process-aware planning, design, and execution of complete bioprocess and analytical unit operations. Meaningful integrations enhance the relevance of your data, while rapid incorporation into your development ecosystem fosters automation and establishes a robust, process-centric data framework. In an industry where precision and efficiency are paramount, IDBS Polar stands out as a vital solution for modern biopharmaceutical development.

Clara provides specialized tools and pre-trained AI models that are driving significant advancements across various sectors, such as healthcare technologies, medical imaging, pharmaceutical development, and genomic research. Delve into the comprehensive process of developing and implementing medical devices through the Holoscan platform. Create containerized AI applications using the Holoscan SDK in conjunction with MONAI, and enhance deployment efficiency in next-gen AI devices utilizing the NVIDIA IGX developer kits. Moreover, the NVIDIA Holoscan SDK is equipped with acceleration libraries tailored for healthcare, alongside pre-trained AI models and sample applications designed for computational medical devices. This combination of resources fosters innovation and efficiency, positioning developers to tackle complex challenges in the medical field.

Prognos stands as the leading provider of specialized lab data, now enhanced by a comprehensive ecosystem of healthcare data assets tailored to address even the most intricate inquiries. Pioneering the market, Prognos established a seamless integration of various lab data types, unlocking their full analytical potential through a robust platform. Currently, this platform connects millions of medical and prescription claims, and its sources continue to expand daily. With access to billions of data points, users can explore harmonized lab data covering 325 million patients, alongside both open and closed medical claims as well as prescription claims. The Prognos Marketplace serves as a user-friendly healthcare data marketplace designed to streamline the data selection and contracting process, allowing users to easily curate and acquire the health data they require at their convenience. This innovative approach empowers businesses to begin with patient-centric data that aligns with their specific operational needs, ensuring they have the right information at their disposal to drive informed decisions. In this way, Prognos not only enhances data accessibility but also fosters a deeper understanding of healthcare dynamics.

The Kanteron Platform assimilated a wide array of medical images, digital pathology slides, genomic sequences, and patient information from various modalities, scanners, sequencers, and databases, delivering a comprehensive data toolkit to all teams within hospital networks. It emphasizes pharmacogenomics to avert adverse medication events and facilitates the application of precision medicine at the point of care by integrating data sources on drug-gene interactions that were formerly only accessible in less user-friendly formats, such as tables found in PDF documents. By incorporating major pharmacogenomic databases like PharmGKB, CGI, DGIdb, and OpenTargets, it enables users to customize their queries according to specific gene families, types of interactions, and drug classifications. Additionally, its adaptable AI allows users to select the dataset that best aligns with their specific use case, applying it effectively to pertinent medical images. This robust functionality not only enhances the accuracy of medical insights but also fosters a more personalized approach to patient care.

Cytel stands out as a prominent global innovator in software for clinical trial design, biometrics, and advanced analytics, focusing on maximizing the efficiency of clinical trials while aiding pharmaceutical companies in harnessing the full scope of both clinical and real-world data. Established in 1987 by renowned statisticians Cyrus Mehta and Nitin Patel, Cytel has consistently been a leader in adaptive clinical trial technology and the field of biostatistics. Its software solutions, notably the East Horizon platform, facilitate accurate trial design and simulation, employing adaptive and Bayesian methodologies to enhance protocols and expedite the drug development process. The East Horizon platform serves as a comprehensive integration of Cytel's reliable software offerings, featuring R integration that significantly improves trial design functions. Furthermore, Cytel provides the Xact software suite, which is an all-encompassing toolkit designed for statistical analysis of small datasets, including those with sparse and missing data. By continuously innovating and expanding its product offerings, Cytel remains committed to providing cutting-edge solutions that meet the evolving needs of clinical research.

QuartzBio is an advanced platform focused on precision medicine that aims to revolutionize the operations of clinical development and translational research teams by creating a cohesive data environment. This environment allows for the integration, synchronization, exploration, and analysis of biospecimen, biomarker, and clinical data through the use of conversational AI technology. Its core offerings include the Precision Medicine AI Agent Platform, which encompasses vital tools such as Sample Intelligence, providing a comprehensive overview of the lifecycle of biospecimens from their collection to long-term storage, complemented by features like automated logistics, stability tracking, and data reconciliation. Furthermore, the platform boasts Biomarker Intelligence, which facilitates the seamless ingestion of assay data across various modalities, including DNA, RNA, protein, and cell-based formats, along with a no-code data-mapping feature, global search capabilities, interactive dashboards, visual analytics, and modules for genomic and cytometry data. To enhance user experience, the Agent Intelligence layer further allows stakeholders to perform natural-language queries, making data interaction more intuitive and efficient than ever before. This innovative approach not only streamlines workflows but also empowers research teams with enhanced insights for better decision-making.

AI-powered drug discovery is a proven technology. Cerella extracts hidden insights from your drug discovery data to reveal the best compounds and most valuable experiment for your project. It can make confident predictions by accurately filling in the missing values. This is especially useful for expensive downstream experiments, which are impossible to predict using other methods. This allows you to do more with sparse and limited data sets.

The software designed to enhance safety, traceability, quality, agility, and integration within your Pharmacotechnics and Medicines Manufacturing Unit is here to assist you. Recognizing that each pharmacy service is unique, we have structured PharmaSuite into specialized functional modules tailored to optimize the management of various units effectively. This includes the oversight of the Pharmacotechnics and Drug Preparation unit, specifically for parenteral mixtures, as well as the administration of parenteral nutrition. With these tools, you can streamline operations and ensure compliance with industry standards.

Harnessing actionable insights from the leading AI-driven clinical analytics platform allows your teams to effectively manage risk and enhance performance throughout studies, systems, sites, and vendor relationships. The cutting-edge technology from Saama is specifically crafted to optimize workflows, automate labor-intensive tasks, and foster improved collaboration among various clinical functions such as operations, medical review, data management, biostatistics, and pharmacovigilance. Both sponsors and CROs depend on Saama's capabilities for data aggregation and AI solutions, which facilitate superior decision-making, minimize delays, and drastically reduce costs and timelines associated with drug development. By leveraging Saama's tools, you can accelerate the pace of clinical trial innovation. When your clinical data is centralized and continuously updated, it simplifies the lives of your ClinOps and medical review teams considerably. Furthermore, Data Managers, often undervalued, can shift their focus from repetitive tasks to the critical data points that truly drive project success, ensuring that their expertise is fully utilized in the process. This transformation not only enhances efficiency but also contributes to the overall quality of clinical outcomes.

Pluto was founded in 2021 by the Wyss Institute of Harvard University. It has been a trusted partner for many life sciences organizations across the country, from biotech start-ups and public biopharma companies. Our cloud-based platform allows scientists to manage all their data, run bioinformatics analysis, and create interactive visualizations that are published-quality. The platform is being used for a variety of biological applications. These include preclinical and translational science research, cell and gene therapies and drug discovery and development.

BIOiSIMTM represents a groundbreaking 'virtual drug development engine' that significantly enhances the drug development sector by effectively identifying drug compounds that are most likely to provide meaningful therapeutic benefits for various diseases or conditions. We provide an array of translational solutions that are tailored to meet the specific needs of your pre-clinical and clinical initiatives. Central to our offerings is the highly validated BIOiSIMTM platform, which supports the development of small molecules, large molecules, and viruses. This innovative platform is underpinned by extensive data derived from thousands of compounds across seven different species, resulting in a level of robustness that is uncommon in the field. Emphasizing human health outcomes, the heart of the platform features a translatability engine that seamlessly converts insights gained from different species. Importantly, the BIOiSIMTM platform can be deployed prior to the initiation of preclinical animal trials, facilitating earlier insights and potentially reducing the costs associated with outsourced experimentation. By integrating these advanced capabilities, we aim to streamline the drug development process and accelerate the journey from discovery to market.

Rare diseases often lack comprehensive research, resulting in insufficient knowledge about essential elements for an effective drug discovery initiative. Our innovative AI platform, Healnet, addresses these issues by scrutinizing vast amounts of drug and disease data to uncover new connections that may lead to potential treatments. Utilizing cutting-edge technologies throughout the discovery and development process allows us to operate multiple phases simultaneously and on a large scale. The conventional approach of focusing on a single disease, target, and drug is overly simplistic, yet it remains the standard for most pharmaceutical companies. The future of drug discovery is driven by AI, characterized by parallel processes and an absence of rigid hypotheses, fundamentally integrating the three core paradigms of drug discovery into a cohesive strategy. This new paradigm not only enhances efficiency but also fosters creativity in developing solutions for complex health challenges.

Founded in 2000, VeraChem LLC aims to enhance the field of computer-aided drug discovery and molecular design by creating advanced computational chemistry techniques that merge innovative basic science with practical applications in research. A key aspect of the company's strategy for product development lies in delivering efficient, high-performance software solutions along with extensive user support. Among the current capabilities of VeraChem's software are predictions for protein-ligand and host-guest binding affinities, rapid and precise calculations of partial atomic charges for drug-like molecules, and the computation of energies and forces utilizing widely-used empirical force fields. Additionally, the software features automatic generation of alternate resonance forms for drug-like compounds, a robust conformational search enabled by the Tork algorithm, and the automatic identification of topological and three-dimensional molecular symmetries. The modular code base of VeraChem’s software packages allows for flexibility and adaptability in meeting diverse research needs, ensuring that users can leverage these tools effectively for their specific applications.

ZONTAL stands out as a prominent provider of digital solutions tailored for the life sciences sector, focusing on optimizing laboratory workflows and speeding up research results through advanced analytics and data science. Their all-encompassing platform features a range of products aimed at improving data management, including the Digital Lab for connecting experts and data, Data Preservation for the protection of critical information, and the Life Science Analytics Platform for seamless integration of analytics into laboratory processes. By prioritizing data to be Findable, Accessible, Interoperable, and Reusable (FAIR), ZONTAL enables organizations to reduce the complexities of data handling, conduct real-time analyses, and tap into limitless analytical capabilities. This transformation not only enhances laboratory operations but also promotes innovation within the modern digital landscape, ensuring that organizations remain competitive and forward-thinking in their research endeavors.

Introducing a groundbreaking medication intelligence platform designed specifically for healthcare professionals, Synapse Medicine stands out as the first of its kind. This innovative platform empowers healthcare providers by delivering trustworthy medical information in real-time, ensuring they have access to independent drug data essential for their practice. With a commitment to supporting all healthcare workers, Synapse Medicine plays a crucial role in promoting proper medication use and minimizing the risk of iatrogenic complications. Just a few clicks can enhance the safety of your prescriptions, as the platform offers continuously updated, reliable medical insights tailored to support prescription decisions. Founded by a team of dedicated healthcare professionals, this service provides a comprehensive overview of drug information, facilitating the appropriate use of medications across various settings. Backed by numerous institutional partners and leading university hospitals, Synapse Medicine truly represents a unique and invaluable resource in the healthcare landscape. By fostering collaboration and innovation, it aims to transform the way medical information is accessed and utilized in clinical practice.

3decision® serves as a cloud-based repository for protein structures, focusing on efficient management of structural data and offering sophisticated analytics to support teams involved in the discovery of small molecules and biologics, thereby expediting the process of structure-based drug design. The platform consolidates and standardizes both experimental and computational protein structures sourced from publicly available databases such as RCSB PDB and AlphaFoldDB, in addition to proprietary datasets, and accommodates formats like PDBx/mmCIF and ModelCIF. This comprehensive approach guarantees seamless access to a variety of structural formats including X-Ray, NMR, cryo-EM, and modeled structures, thereby promoting collaboration and bolstering research initiatives. In addition to its storage capabilities, 3decision® enhances each entry with valuable metadata and sequence information, which encompasses details on protein-ligand interactions, antibody annotations, and specifics about binding sites. Equipped with advanced analytical instruments, the platform is capable of pinpointing druggable sites, evaluating off-target risks, and facilitating comparisons of binding sites, which collectively transform extensive structural datasets into practical insights that can drive research forward. Furthermore, its cloud-based architecture fosters enhanced collaboration among research teams, making it easier for scientists to share findings and insights, ultimately leading to more innovative approaches in drug discovery and development.

Flywheel provides comprehensive data management solutions to researchers looking to improve productivity and collaboration in imaging research and clinical trials, multi-center studies, and machine learning. Flywheel provides end-to-end solutions that streamline data ingestion and curate it to common standards. We also automate processing and machine-learning pipelines. Our platform allows for secure collaboration in the life sciences, clinical, academic, as well as AI, industries. Cross-platform data and algorithm integration, secure and compliant data discovery among a global network, and cloud-scalable and on-premise computational workflows to support research and clinical applications. Flywheel is a data curation platform that supports multi-modality research. It can manage a wide range of data types, including digital pathology, imaging files, clinical EMR data and omics, as well as instruments.

The L7 Enterprise Science Platform (L7|ESP®) is a comprehensive platform designed to contextualize data and remove business silos through process orchestration. This all-in-one solution supports the digitalization of data and scientific processes within life sciences organizations. It includes native applications like L7 LIMS, L7 Notebooks, L7 MES, and L7 Scheduling. L7|ESP seamlessly integrates with third-party applications, lab instruments, and devices to consolidate all data into a unified model. Featuring a low-code/no-code workflow designer and numerous pre-built connectors, it ensures rapid implementation and full automation. Utilizing a single data model, L7|ESP enhances advanced bioinformatics, AI, and ML to provide new scientific and operational insights. L7|ESP addresses the data and lab management needs and challenges within the life sciences sector, specifically targeting: ● Research and Diagnostics ● Pharma and CDMO ● Clinical Sample Management Explore the L7 Resource Center for on-demand recordings, case studies, datasheets, and more: l7informatics dot com/resource-center

Proteins, which are remarkably complex machines, play a crucial role not only in the biological functions of your body but also in every living organism's processes. They serve as the fundamental units of life. As of now, there are approximately 100 million identified proteins, with discoveries being made regularly. Each protein possesses a distinctive three-dimensional shape that is essential to its functionality and purpose. However, determining a protein's precise structure is often a costly and lengthy endeavor, resulting in an understanding of only a small percentage of the proteins recognized by science. Addressing this growing disparity and developing methods to predict the structures of millions of yet-to-be-discovered proteins could significantly advance our ability to combat diseases, expedite the discovery of new treatments, and potentially unveil the secrets of life's mechanisms. The implications of such advancements could transform both medicine and our understanding of biology.

Genedata Biologics® enhances the development of biotherapeutics, including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs, providing a comprehensive solution for the industry. Recognized as the leading platform in the field, it seamlessly unifies all discovery workflows, allowing researchers to prioritize genuine innovation. By utilizing a pioneering platform that was purposefully created to digitalize the biotherapeutic discovery process, research can be accelerated significantly. The platform simplifies intricate R&D tasks by facilitating the design, tracking, testing, and evaluation of novel biotherapeutic drugs. It is compatible with various formats, such as antibodies, bi- or multi-specifics, ADCs, innovative scaffolds, and therapeutic proteins, as well as engineered therapeutic cell lines like TCRs and CAR-T cells. Functioning as a comprehensive end-to-end data backbone, Genedata Biologics connects all R&D processes, including library design, immunization, selection and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, ultimately leading to thorough assessments of candidate developability and manufacturability. This holistic integration ensures that researchers can make informed decisions and push the boundaries of biotherapeutic innovation effectively.

Harnessing RNA sequencing (RNA-seq) data alongside Artificial Intelligence presents both a crucial necessity and a significant opportunity for creating therapies aimed at correcting splicing errors. By leveraging machine learning, we can uncover novel splicing errors and swiftly formulate therapeutic compounds to address them. Our AI platform, SpliceCore, is specifically designed for discovering RNA therapeutics. This cutting-edge technology focuses on analyzing RNA sequencing data with unparalleled efficiency. It can swiftly identify, evaluate, and validate potential drug targets, outpacing traditional methodologies. Central to SpliceCore is our unique repository containing over 5 million potential RNA splicing errors, making it the largest of its kind globally and instrumental for testing any RNA sequencing dataset submitted for analysis. The integration of scalable cloud computing allows us to handle vast quantities of RNA sequencing data in a way that is not only efficient but also cost-effective, significantly speeding up the pace of therapeutic advancements. This innovative approach promises to revolutionize the landscape of RNA therapeutics.

Efficiently generating reports for NGS-based clinical tests necessitates a well-established and sophisticated platform that can automatically prioritize variants, interpret clinical data, and create comprehensive reports. Strand Omics serves as a rapid, HIPAA-compliant cloud platform that enhances our clinical diagnostics efforts, having been refined over four years through the analysis of more than 10,000 clinical reports and numerous peer-reviewed studies. This platform integrates advanced bioinformatics algorithms with curated databases, intuitive visualization tools, and robust reporting features. It is designed with specialized workflows tailored for both rare inherited conditions and somatic tumor profiling assays. Additionally, the system boasts a library of over 10,000 somatic variants that have been curated for their oncogenic potential, alongside 100 genes selected for their druggability across various cancer types, as well as 500 drugs that have been validated for efficacy against multiple cancers. Furthermore, its comprehensive approach ensures that healthcare professionals have access to critical data, ultimately facilitating informed decision-making in patient care.

Uncover biological markers, generate insights into the mechanisms of disease, identify novel pharmaceuticals, or detect variations in protein concentrations through a meticulously structured series of experiments. We have simplified the process of harnessing the potential of mass spectrometry and proteomics, enabling you to concentrate on the intricacies of biology and advance toward groundbreaking discoveries. Our automated and consistent workflow facilitates faster initiation and completion of experiments, granting you the authority and adaptability to make timely decisions. By prioritizing biological insights and fostering collaborative efforts, our scalable proteomics data processing system is designed for repeated use. We have delegated intensive and repetitive tasks to the cloud, ensuring a smooth and satisfying experience. Our sophisticated proteomics workflow effectively integrates numerous complex elements, allowing for the efficient analysis and processing of larger-scale experiments, ultimately enhancing the research journey. Thus, with our innovative approach, researchers can now delve deeper into the molecular landscape and achieve more significant breakthroughs than ever before.

Established in Chicago, Illinois, PatientIQ provides a platform for healthcare providers, medical device manufacturers, life sciences companies, and payers to enhance their practices through data-driven medicine. It is recognized as the largest collaborative platform for healthcare professionals aimed at improving patient outcomes. By equipping healthcare providers with cutting-edge technology, PatientIQ fosters a culture of data-driven medical practice. In the competitive landscape of the U.S. healthcare market, all parties involved face mounting pressure to demonstrate their value effectively. A key factor in determining "value" lies in the objective measurement of patient outcomes. However, quantifying these outcomes presents challenges that are costly, complex, and fraught with technological obstacles. Despite these difficulties, outcomes represent the most significant currency in the future of value-based healthcare. Thus, a clear and reliable solution to systematically measure, analyze, and benchmark outcomes among various stakeholders presents a significant opportunity for growth in the digital health sector. As the industry evolves, the need for such innovative solutions will only become more pronounced.

ScienceDesk's data automation simplifies the integration of artificial intelligence within the field of materials science. This tool serves as a practical solution for teams to consistently implement and utilize the latest AI algorithms in their daily workflows. It features customizable attributes, universal identifiers, QR codes, and a robust search engine that connects sample data with experimental results. As a groundbreaking platform, ScienceDesk facilitates collaboration among scientists and engineers, allowing them to engage with and glean insights from their experimental findings. However, the full potential of this resource remains untapped due to the diverse data formats and a reliance on specialists to manually retrieve targeted information. The ScienceDesk research data management system addresses this challenge by merging documentation with data analysis within a thoughtfully designed data structure. Our algorithms empower researchers and scientists, granting them comprehensive command over their data. They can not only exchange datasets but also share their analytical expertise, fostering a more collaborative research environment. Overall, ScienceDesk enhances data accessibility and encourages innovative approaches in scientific investigation.

MMIT (Managed Markets Insight & Technology) provides a robust analytics and healthcare market access platform that consolidates critical data regarding coverage, policy, restrictions, payers, and real-world insights, enabling life sciences and healthcare organizations to navigate the complexities of therapy coverage, reimbursement, and accessibility within the U.S. healthcare landscape. The MMIT Platform acts as a comprehensive resource where users can delve into a variety of integrated solutions, such as formulary intelligence, medical policy insights, payer landscape and enrollment information, tools for coverage searches, API connectivity, and analytics tailored to support commercialization efforts, competitive assessments, and strategies for patient access. Additionally, it offers in-depth analysis of drug coverage statuses, restrictions, payer dynamics, and market segmentation, featuring tools designed to assess patient access hurdles, guide field engagement initiatives, anticipate policy changes, and seamlessly incorporate coverage information. Ultimately, MMIT empowers its users to make informed decisions that enhance their strategic objectives in the healthcare sector.

We have established ourselves as frontrunners in the fields of ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology, a status achieved through the achievements our clients have experienced while partnering with us. Leveraging over two decades of expertise, our skilled team excels at transforming complex scientific concepts into accessible software solutions, while also offering specialized consulting services that bolster drug discovery, clinical development research, and regulatory submission processes. Our dedication to client success drives our continuous improvement and innovation in these critical areas.

The Sapio Scientific Data Cloud is an innovative scientific data management platform that intelligently consolidates and contextualizes laboratory data, assay outcomes, instrument outputs, archives, and external ELN/LIMS records into a cohesive, searchable interface that requires no programming skills. This system facilitates automated data acquisition and interpretation from more than 200 instrument adaptors, employs semantic search capabilities driven by ontological frameworks, and features integrated charting along with sophisticated neural-network analytics such as ANOVA, best-response curves, and flow-cytometry gating. Furthermore, it delivers AI-generated insights to enhance research efficiency. To ensure the protection of sensitive information, it offers secure, role-based access and comprehensive data archiving solutions, while providing interactive viewers for proteins, molecules, plasmids, and system-wide analyses that empower scientists to delve into their findings. Additionally, the seamless integration with Sapio LIMS and ELN systems ensures that data is automatically linked with relevant samples, experiments, and entities for streamlined research workflows. This powerful combination of features makes the Sapio Scientific Data Cloud an essential tool for modern laboratories.

Discover valuable insights within your data by utilizing the Cortellis™ suite of life science intelligence tools, enabling you to make more informed decisions throughout the entire R&D process. We have alleviated the burden of gathering, integrating, and analyzing data, allowing you to concentrate on the essential choices necessary for expediting your products' market entry. With a unique combination of extensive, high-quality data, fortified by profound domain knowledge, industry insight, and therapeutic expertise, Cortellis reveals crucial insights that facilitate data-driven decisions, ultimately speeding up innovation. Access tailored, actionable responses to your specific inquiries throughout the R&D lifecycle, drawing from the most comprehensive and in-depth intelligence sources available. By incorporating Cortellis into your daily routine, you can significantly enhance the pace of innovation and streamline your workflow. This makes Cortellis not just a tool, but a vital partner in your path to success.

The process of introducing a new medication to the market, starting from initial development to the final launch, is both time-intensive and heavily regulated, often spanning over a decade or more. Achieving success in this endeavor hinges on the timely availability of precise analytical data, which is essential for making informed decisions during the early stages of development and reducing the likelihood of setbacks later on. Modern drug development primarily follows a systematic approach, with the crucial first step usually being the identification of a biological target to concentrate efforts on. This target identification demands a comprehensive understanding of the characteristics of the candidates, enabling swift and reliable identification of the most promising options. After establishing a biological target, the next significant hurdle is identifying the most advantageous lead molecules, which entails discovering potential drug candidates—these may include small organic compounds or biological constructs with therapeutic capabilities. Thus, the entire journey from concept to market is a complex interplay of scientific insight and strategic decision-making.

StarDrop™, a comprehensive suite of integrated software, delivers the best in silico technology within a highly visual interface. StarDrop™, which allows seamless flow between the latest data, predictive modeling, and decision-making regarding the next round or synthesis, improves the speed, efficiency and productivity of the discovery process. A balance of different properties is essential for successful compounds. StarDrop™, which guides you through the multi-parameter optimization challenge, helps you target compounds with the highest chance of success. It also saves you time and resources by allowing you to synthesize fewer compounds and test them less often.